Outcomes of patients with advanced stage ovarian cancer with intestinal metastasis
Abstract
Objectives: The aim of this study is to evaluate the results of advanced stage (stage IIIB-IVB) ovarian cancer (OC) patients with intestinal metastasis, and to investigate the factors that affect survival.
Material and methods: Patients who underwent cytoreductive surgery (CS) for FIGO stage IIIB-IVB OC with metastasis in the intestinal system, at Tepecik Research and Treatment Hospital between 2008–2014, were analyzed retrospectively. Patients with borderline ovarian tumor; those who had previously undergone radiation therapy and/or hysterectomy and patients having secondary or tertiary cytoreduction were excluded and 49 patients were included and analyzed in this study. Hysterectomy, bilateral salpingo-oopherectomy, pelvic and para-aortic lymph node sampling, resection of bulky lymph nodes and omentectomy were performed. Optimal cytoreduction was accepted as that which left residual tumor ≤ one cm maximum size.
Results: The risk factors affecting OS interval were investigated according to Cox’ regression analysis. Optimality of the primary CS (P = 0.008 and HR = 5.202) and cancer stage (P = 0.016 and HR = 6.083) were found to be statistically significant factors.
Conclusions: Achieving optimal CS is the most important aim for the general surgeon carrying out an intestinal resection procedure. Although resection procedures are superior in providing the desired optimal results when compared to excision surgery, their higher complication rates and subsequent lower quality of life must be taken into consideration when choosing either resection or excision methods; surgical intervention should always be kept to the minimum possible.
Keywords: ovarian neoplasmsintestinal neoplasmsgynecologic surgical procedures
References
- Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin. 1999; 49(1): 8–31.
- Vidal F, Guerby P, Luyckx M, et al. Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis? PLoS One. 2016; 11(1): e0147787.
- Minig L, Zorrero C, Iserte PP, et al. Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients. World J Methodol. 2015; 5(4): 196–202.
- Pohl R, Dallenbach-Hellweg G, Plügge T, et al. Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gynaecol Oncol. 1984; 5(3): 160–169.
- Kato K, Nishikimi K, Tate S, et al. Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration. World J Surg Oncol. 2015; 13: 230.
- Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004; 14(1): 35–41.
- Randall TC, Rubin SC. Cytoreductive surgery for ovarian cancer. Surg Clin North Am. 2001; 81(4): 871–883.
- Peiretti M, Bristow RE, Zapardiel I, et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol. 2012; 126(2): 220–223.
- Hertel H, Diebolder H, Herrmann J, et al. Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol. 2001; 83(3): 481–484.
- Sonnendecker EW, Beale PG. Rectosigmoid resection without colostomy during primary cytoreductive surgery for ovarian carcinoma. Int Surg. 1989; 74(1): 10–12.
- Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5): 1248–1259.
- Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006; 103(3): 977–984.
- Plotti F, Montera R, Aloisi A, et al. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer. Eur J Surg Oncol. 2016; 42(3): 383–390.
